Ascendo developing solution to rapid virus mutations

Ascendo has developed a proprietary NanoCherub electric-kinetic nanocomplex antigen adjuvant and delivery platform for a COVID-19 vaccine, as reported Taipei Times.

Using quantum mechanics calculations, the company can produce effective vaccines rapidly, with a precise and flexible technology avoiding the need for the constant testing of more traditional approaches.

The ASD254 vaccine developed by the company showed excellent results in animal studies using mice, with all vaccinated animals receiving 100% immune protection when tested with the live virus.

Ascendo soon plans to apply to the FDA for Phase I trials, hoping to enter mass production next year.

The drug delivery platform can reportedly shorten development times and respond to virus mutations.

Meanwhile, the NanoCherub  electric-kinetic nanocomplex can consistently induce balanced and strong Th1/Th2 immunity against encapsulated antigens, with the added advantage of the vaccines only needing to be stored at 2°C to 8°C.